Last reviewed · How we verify
NCT07068971: SWAN
Sleep Well At Night
NA trial testing Online cognitive behavioural therapy for insomnia, bright light therapy, activity in Sleep Disturbance in Advanced Cancer in 30 participants. Enrolling by invitation.
24 August 2025
Quick facts
| Lead sponsor | Our Lady's Hospice and Care Services |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 30 |
| Start date | 19 August 2024 |
| Primary completion | 24 August 2025 |
| Estimated completion | 24 August 2025 |
| Sites | 1 location across Ireland |
Drugs / interventions tested
- Online cognitive behavioural therapy for insomnia, bright light therapy, activity
Conditions studied
- Sleep Disturbance in Advanced Cancer — all drugs for Sleep Disturbance in Advanced Cancer →
Sponsor
Our Lady's Hospice and Care Services
Who can join
18 and older, any sex, with Sleep Disturbance in Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Research has shown that the incidence of sleep disturbances in people with cancer is much higher than in the general population. Sleep problems can lead to worse symptoms, quality of life, and potentially impact outcomes. The most common treatment of sleep disturbances is medication which often comes with unwanted side-effects and risk. This study aims to test whether a non-drug intervention can be given to people with cancer to help with sleep disturbances. The study will take place over 8-weeks. The first and final week of the study involves assessments (further described below) while the intervention will take place over weeks 2-7. The intervention involves an online cognitive behavioural therapy course, daily bright light therapy and engaging with an activity plan. The initial review aims to identify any reversible causes of the sleep disturbance, including reviewing uncontrolled symptoms and medications. Cognitive behavioural therapy for insomnia (CBT-I) has been shown to be effective at improving the time it takes for people to fall asleep and reducing the amount of time you wake up in the night. Light therapy mimics our natural exposure to sunlight. Light exposure may help to improve sleep during the night, mood, and activity or attention levels during the day. Physical activity levels will also be reviewed. Interests and barriers to activity will be discussed and goals will be set for activity. This will be reviewed weekly. Questionnaires will be completed in the first and final week of the study to assess sleep, symptoms and quality of life. Wrist actigraphy, thigh accelerometry and a sleep diary will also be used on the first and final week of the study to assess sleep, activity and subjective sleep patterns.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07068971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Our Lady's Hospice and Care Services trials
Trials by the same sponsor.
- NCT07512505 — Remote Vital Sign Monitoring in Palliative Care Patients Using a Wearable ECG Monitor · recruiting
- NCT07411105 — Cognition in Older Adults With Cancer Receiving Systemic Anti-Cancer Therapy · active not recruiting
- NCT06587321 — Remote Assessment of Signs and Symptoms in Palliative Care · recruiting
- NCT06287294 — An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer · recruiting
- NCT06286982 — The Oral Symptom Assessment Scale in Older Patients With Frailty · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07068971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Our Lady's Hospice and Care Services
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07068971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing